Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177194 | 0.76 | MEN1 (0.33) | — | |
| SCHEMBL16967740 | 0.76 | MEN1 (0.33) | — | |
| SCHEMBL3167074 | 0.76 | TSHR (0.34) | LMNA | |
| SCHEMBL3161545 | 0.76 | MEN1 (0.33) | — | |
| SCHEMBL20377961 | 0.74 | — | — | |
| SCHEMBL20377969 | 0.74 | — | — | |
| SCHEMBL600244 | 0.74 | — | — | |
| SCHEMBL3168253 | 0.70 | MAPT (0.33) | MAPTTDP1 | |
| SCHEMBL20810267 | 0.69 | KDM4E (0.32) | MAPTALDH1A1PTGS2NFKB1 | |
| SCHEMBL8768901 | 0.68 | CYP2D6 (0.33) | LMNAMAPTCYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| US-11529342-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3006023-B1 | SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190151301-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3006024-B1 | BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10149845-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-12-11 | — | — | US | disclosed |
| US-10039730-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170189358-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170181989-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-06-29 | — | — | US | disclosed |
| US-9675604-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-06-13 | — | — | US | disclosed |
| US-6248775-B1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. | 2001-06-19 | — | — | US | disclosed |
| US-6211176-B1 | AIDS TREATMENT | G. D. SEARLE & CO. | 2001-04-03 | — | — | US | disclosed |
| US-6172082-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G. D. SEARLE & CO. | 2001-01-09 | — | — | US | disclosed |
| US-6156768-A | Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6060476-A | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2000-05-09 | — | — | US | disclosed |
| WO-2000023598-A1 | AMINOACYLASE AND ITS USE IN THE PRODUCTION OF D-AMINOACIDS | CHIROTECH TECHNOLOGY LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
| EP-0715618-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0656887-A1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0132441-A1 | ANTIBACTERIAL PEPTIDES | UNIVERSITY PATENTS, INC. (US) | 1985-02-06 | — | — | EP | disclosed |
| WO-1984002905-A1 | ANTIBACTERIAL PEPTIDES | UNIVERSITY PATENTS INC (US) | 1984-08-02 | — | — | WO | disclosed |